Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab in NMDAR or LGI1 Encephalitis
NCT05503264Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of satralizumab in Anti-N-methyl-D-aspartate receptor encephalitis, leucine-rich glioma-inactivated 1 antibody encephalitis, sponsored by Roche. Started Sep 2022; status: active, not recruiting.
02
Drugs
satralizumab
03
Conditions
Anti-N-methyl-D-aspartate receptor encephalitisleucine-rich glioma-inactivated 1 antibody encephalitis
Beyond the preview
Go deeper on NCT05503264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05503264.